Those who have taken an interest in Clinuvel will have learned with joy that, on Monday February 6th, the company announced its first official filing for SCENESSE® (afamelanotide) with the European Medicines Agency. It has taken our teams around six years to arrive at this point. Benchmarked against peer companies, it is a relatively swift development path for a first-in-class drug; we first publicly announced our erythropoietic protoporphyria (EPP) program in September 2006. It is an opportune moment to reflect briefly on how we reached this milestone and then discuss the steps that must be taken from here. (more…)
In a striking new campaign, the 
Cancer Council Australia has launched one of the strongest public attacks to date on the use and regulation of sunbeds in the country. This follows a report that some solarium devices emit UV radiation six times stronger than the sun at midday in Australia.
Held biennially, the Porphyrins & Porphyrias conference (P&P) is the world’s largest gathering on the porphyrias – a group of metabolic disorders causing biochemical disruptions in the pathway of the body which synthesizes haem (heme).
Since our announcement last year that Clinuvel would commence a new 
As part of our ongoing guest blogger series, we’ve invited Lee Thomas to share his experiences on the Clinuvel blog. Lee is an award winning US journalist who has spoken widely about his experiences with vitiligo, including in a documentary entitled ‘Turning White’. You can learn more about Lee at 
As part of our ongoing focus on erythropoietic protoporphyria (EPP), we’ve invited Victoria to share her experiences with EPP as a guest blogger. You can read Victoria’s first post 
